Senator Rick Scott has introduced the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act during a U.S. Senate Special Committee on Aging hearing. The proposed legislation aims to require prescription drug labels to include information about where medications are produced.
This legislative effort follows a bipartisan investigative report led by Senator Scott as chairman of the Aging Committee. The report examined vulnerabilities in the generic drug supply chain and called for increased accountability. According to the findings, the United States is increasingly dependent on pharmaceutical products manufactured overseas, particularly antibiotics from China and generic drugs from India.
Scott stated, “It is alarming just how many medicines Americans depend on are made overseas, in places like Communist China and India with limited transparency and oversight, leaving patients blindsided about where their drugs come from and unknowingly putting themselves at increased risk of death.”
The CLEAR LABELS Act seeks to improve transparency so that Americans have access to information about the origins of their medications and can be aware of potential risks associated with drugs produced outside the United States.
